FTH

SEC source: 0001209191-23-021541 · doc4a.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,003

F1 · security: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F2 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported.

SEC source: 0001209191-23-021540 · doc4a.xml · derivative · entry 3

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2023-02-14

F4 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-021540 · doc4a.xml · nonDerivative · entry 2

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,513

F3 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares.

SEC source: 0001209191-23-021540 · doc4a.xml · nonDerivative · entry 1

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,313

F1 · security: This amendment is being filed solely to correct the number of shares beneficially owned, which the original filing overreported by two shares.

F2 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

SEC source: 0001209191-23-048968 · doc4.xml · nonDerivative · entry 1

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,130

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-23-048967 · doc4.xml · nonDerivative · entry 1

van der Horst Edward · CIK 0001957499 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,913

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-23-048966 · doc4.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,811

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-23-048965 · doc4.xml · nonDerivative · entry 1

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,089

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-22-036665 · doc4.xml · derivative · entry 2

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036665 · doc4.xml · nonDerivative · entry 1

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,132

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001567619-22-012842 · doc1.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012842 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,235,954

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012841 · doc1.xml · derivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012841 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,235,954

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-22-036671 · doc4.xml · derivative · entry 2

Vojta Deneen · CIK 0001843509 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036671 · doc4.xml · nonDerivative · entry 1

Vojta Deneen · CIK 0001843509 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,466

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036669 · doc4.xml · derivative · entry 2

English Jessie · CIK 0001854515 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036669 · doc4.xml · nonDerivative · entry 1

English Jessie · CIK 0001854515 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,466

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036668 · doc4.xml · derivative · entry 3

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036668 · doc4.xml · nonDerivative · entry 1

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,466

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036667 · doc4.xml · derivative · entry 2

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036667 · doc4.xml · nonDerivative · entry 1

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,466

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036666 · doc4.xml · derivative · entry 2

Broder Samuel · CIK 0001340543 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-22-036666 · doc4.xml · nonDerivative · entry 1

Broder Samuel · CIK 0001340543 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,466

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001567619-22-014723 · doc1.xml · derivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-014723 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,235,956

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F4 · balance_after: Amendment filed solely to correct the number of shares owned.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-23-004608 · doc1.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-23-004608 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,235,956

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F4 · balance_after: Amendment filed solely to correct the number of shares owned.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-22-034040 · doc4.xml · derivative · entry 1

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable as to 25% of the shares underlying the option on June 1, 2023, and the remaining 75% of the shares underlying the Option shall vest and become exercisable in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001209191-22-017684 · doc4.xml · derivative · entry 3

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,100

Underlying: Common Stock · 29,100 shares

Expires 2032-03-07

F4 · derivative.exercise_date: The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, March 8, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001209191-22-017684 · doc4.xml · nonDerivative · entry 2

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,933

F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, on March 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

F3 · balance_after: Includes 8,933 shares acquired by the Reporting Person as of March 8, 2022 as an RSU award.

SEC source: 0001209191-22-017684 · doc4.xml · nonDerivative · entry 1

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,933

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in three equal annual installments on each of March 8, 2023, March 8, 2024, and March 8, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001567619-22-006007 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,231,989

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-006006 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,231,989

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012647 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,231,488

F1 · balance_after: This Form 4/A is being filed solely to correct the number of shares beneficially owned following the transaction reported herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012646 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,231,488

F1 · balance_after: This Form 4/A is being filed solely to correct the number of shares beneficially owned following the transaction reported herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005913 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,230,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005915 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,230,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005913 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228,328

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005915 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,228,328

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005792 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,228,286

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005791 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228,286

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005518 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,225,786

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005517 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,225,786

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005518 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,210,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005517 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,210,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005191 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,208,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005190 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,208,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005191 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,193,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005190 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,193,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.